Your search history is turned on.
Date: April 12, 2024 Jurisdictions: Alberta, British Columbia, Ontario
LEGAL_43081416.1 Navco Announces Marketing Campaign Vancouver, British Columbia--(April 12, 2024) - Navco Pharmaceuticals Inc. (TSXV: NAV) (Navco or the Company), announces that it has entered a contract with SOF Marketing for $300,000 CAD to broaden the company's reach within the investment community, to increase investor awareness of the com...
Date: March 28, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Microsoft Word - tmpECDA.docx LEGAL_43556515.1 NAVCO PHARMACEUTICALS INC. (the Company) c/o Suite 1500 1055 West Georgia Street Vancouver, British Columbia, V6E 4N7 Form 51-102F6V Statement of Executive Compensation Venture Issuers (for financial year ended September 30, 2023) STATEMENT OF EXECUTIVE COMPENSATION VENTURE ISSUERS GENERAL The following inf...
To All Applicable Exchanges and Securities Administrators Subject: NAVCO Pharmaceuticals Inc. (the "Issuer") Notice of Meeting and Record Date Dear Sir/Madam: Annual General Meeting June 4, 2024 April 23, 2024 April 23, 2024 April 23, 2024 Common Shares CA63942R1091 No No No No Yours truly, Odyssey Trust Com...
Date: March 14, 2024 Jurisdictions: Alberta, British Columbia, Ontario
LEGAL_43408009.1 Navco Pharmaceuticals Inc. Announces Stock Option Grants Vancouver, British Columbia--(March 14, 2024) - Navco Pharmaceuticals Inc. (TSXV: NAV) (Navco or the Company, formerly, BMGB Capital Corp.) announces that it has granted an aggregate of 3,900,000 stock options (the Options) to certain officers, directors and consultants of the...
Date: February 28, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Geoffrey Lee, Chief Executive Officer of Navco Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report (the interim filings) of Navco Pharmaceuticals Inc. (the issuer) for the interim period ended December 31, 2023. 2. No mis...
Date: February 27, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Chris Cooper, Chief Financial Officer of Navco Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report (the interim filings) of Navco Pharmaceuticals Inc. (the issuer) for the interim period ended December 31, 2023. 2. No mis...
Drexel MD&A June 30 2011 (00089196-2).DOC NAVCO PHARMACEUTICALS INC. MANAGEMENT DISCUSSION & ANALYSIS For the Period Ended December 31, 2023 This Management Discussion and Analysis (MD&A) of NAVCO Pharmaceuticals Inc (NAVCO or the Company) has been prepared by management as of February 27, 2024, and should be read together with the finan...
CONAME Financial Statements NAVCO Pharmaceuticals Inc. As at December 31, 2023 (Expressed in Canadian dollars) NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if ...
Date: January 30, 2024 Jurisdictions: Alberta, British Columbia, Ontario
LEGAL_43081416.1 Navco Pharmaceuticals Inc. Announces Proposed Warrant Amendment Vancouver, British Columbia--(January 30, 2024) - Navco Pharmaceuticals Inc. (TSXV: NAV) (Navco or the Company, formerly, BMGB Capital Corp.) announces that it intends to amend the exercise price of certain common share purchase warrants (the...